Treace Medical Concepts Reports First Quarter 2026 Financial Results
Treace Medical Concepts reported Q1 2026 revenue of $47.2 million, a 10% decrease from the $52.6 million reported in Q1 2025. The company posted a net loss of $18.0 million and an adjusted EBITDA loss of $5.5 million in Q1 2026, compared to a net loss of $15.9 million and an adjusted EBITDA loss of $3.8 million in Q1 2025. Treace reaffirmed its full-year 2026 revenue guidance in the range of $202 million to $212 million, representing a decline of 5% to 0% from 2025. The company also expects a 50% reduction in cash usage for the full year 2026.
Key figures
- Eps Beat
- 0
- Revenue
- 47198000
- Guidance
- 2026 revenue $202M-$212M, representing a decline of 5% to 0%; Adjusted EBITDA loss $4.0M-$6.0M; expected 50% reduction in cash usage
- Revenue Yoy
- -10%
- Net loss
- 17961000
- Gross profit
- 37407000
- Total assets
- 184102000
- Total liabilities
- 106911000
- Operating expenses
- 54574000
- Marketable securities
- 42310000
- Cash and cash equivalents
- 9544000
- Total stockholders equity
- 77191000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.